“However, the guidelines also acknowledge that individual dose-tapering schedules are needed and that there is no ‘one size fits all’ dose in management of this condition,” he adds.
Mary Beth Nierengarten is a freelance medical journalist based in St. Paul, Minn.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica. Arthritis Rheumatol. 2015 Oct;67(10):2569–2580.
- ACR releases new publications focused on polymyalgia rheumatica and gout [news release]. Atlanta: American College of Rheumatology. 2015 Sep 10.
- Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: The mess we are now in and what we need to do about it. Arthritis Rheum. 2006 Aug 15;55(4):518–520.
- Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594–1597.
- Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484–492.
- Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2012 Apr;64(4):943–954.